Jamie Smith
Media Relations
Email: jamie.smith@molnlycke.com
Phone: +46 723 757507
Mölnlycke Health Care makes record investment to increase global manufacturing capacity with expansion in Maine, USA
Gothenburg, Sweden, 26 June 2025. Mölnlycke Health Care, a global leader in MedTech, today announces its largest investment to date: a €115 million expansion of its wound care manufacturing capacity in Brunswick, Maine, USA.
Rendering of facility by SMRT.
This move is a key part of Mölnlycke’s ongoing localisation strategy, aimed at producing products where they are sold. It addresses increasing US customer demand and underscores Mölnlycke's commitment to growth, customer centricity and sustainability.
Zlatko Rihter, CEO of Mölnlycke, says: "This expansion strengthens our US presence and our mission to free patients and caregivers from the burden of wounds. With increased manufacturing capacity, we’re ready to meet the growing needs of our customers and take our US growth to the next level."
Over the next five years, Mölnlycke will invest around €115 million to secure the supply of Mölnlycke's life-changing wound care products in the world’s largest medtech market. The expansion will create new job opportunities, increasing the local workforce by 10%, as well as engaging local contractors.
By expanding its US manufacturing capacity, Mölnlycke will strengthen its supply chain resilience, mitigate risk exposure and ensure the timely delivery of products to healthcare providers and patients across the US and beyond.
The state-of-the-art facility will support Mölnlycke’s long-term sustainability goals by utilising renewable energy sources like wind and solar power and reducing climate impact through streamlined logistics.
Additionally, the expansion will integrate cutting-edge machinery and technical equipment from US suppliers to enable high quality and efficient production of advanced wound care products.
Chris Biddle, General Manager US Manufacturing, Wound Care, Mölnlycke, says, “This expansion is a very big deal and the result of over a year’s hard work. Besides creating new jobs, it will drive workforce development and bring technological advancements. It’s a win for Mölnlycke, for the local community and for patients. We’re excited about the positive impact it will have locally in Maine and across the broader US healthcare landscape.”
For more information, please contact
Latest news
Read all news-
Mölnlycke joins ALPS as Gold Strategic Partner to advance limb preservation
Mölnlycke has joined the American Limb Preservation Society (ALPS) as an official Gold Strategic Partner, reinforcing a shared commitment to improving outcomes for patients at risk of amputation due to diabetic foot complications.
-
New consensus document highlights need to address post-operative blistering to improve patient outcomes
At Mölnlycke Health Care, we work alongside clinicians, researchers and healthcare experts to advance evidence-based care and help raise standards for post-operative care.
-
From pressure to potential: new report reveals opportunity to increase healthcare capacity
Gothenburg, Sweden. 21 September 2026. Mölnlycke Health Care (Mölnlycke®), a global leader in MedTech, today announces the launch of The Hidden Capacity Report, a new international report revealing significant opportunities to expand day surgery and help healthcare systems improve efficiency, increase surgical throughput and enhance patient outcomes.
-
Mölnlycke to separate its surgical solutions business into a standalone company
Gothenburg, Sweden. 16 September 2026. Mölnlycke®, a global leader in MedTech, announces its intention to separate its Operating Room Solutions (ORS) and Gloves businesses into a new standalone company (referred to here as “Mölnlycke Surgical”). The separation is intended to create conditions for both Mölnlycke and Mölnlycke Surgical to reach their full potential and drive value creation long-term.
-
Major Scottish Hospital Adopts Steriwave®
UK’s Largest Hip and Knee Replacement Centre Becomes First in Scotland to Adopt Steriwave® Nasal Photodisinfection.
-
5 million and growing: scaling Granudacyn® production in Salzburg
-
First factory in China reaches key milestone and strengthens Mölnlycke’s global manufacturing network
Mölnlycke has completed construction of its first manufacturing facility in China, marking a major milestone in the company's growth journey and strengthening its ability to serve one of the world's largest and fastest growing healthcare markets.
-
Mölnlycke Health Care accelerates U.S. growth journey with three wound care product launches
Peachtree Corners, GA. 7 July, 2026. Mölnlycke Health Care (Mölnlycke®), a global leader in MedTech, has launched three product innovations in the U.S. since the start of 2026. Designed to expand access to advanced wound care solutions and strengthen the company’s U.S. presence, the portfolio expansion also supports long-term value creation across key market segments.
-
Changes to Mölnlycke Health Care Board of Directors
Gothenburg, Sweden. 23 June 2026. Mölnlycke Health Care (Mölnlycke®), a global leader in MedTech, today announces changes to its Board of Directors. Christian Cederholm will leave his Board assignment, while Filippa Stenberg will take his place as member of the Board. Thomas Kidane will step in as deputy board member.